10Dec/13

Studies Evaluating REVLIMID® (Lenalidomide) in Lymphoma Presented at ASH – Business Wire (press release)

Studies Evaluating REVLIMID® (Lenalidomide) in Lymphoma Presented at ASH
Business Wire (press release)
In the first study, Dr. Nishitha M. Reddy evaluated whether maintenance treatment with lenalidomide plus rituximab would result in a clinically significant reduction in relapse rates when compared with lenalidomide alone. DLBCL patients with an 

and more »

10Dec/13

Positive Data on Infinity Pharma Candidate – Zacks.com

Positive Data on Infinity Pharma Candidate
Zacks.com
The study will evaluate the safety and efficacy of IPI-145 in iNHL patients whose disease is refractory to radioimmunotherapy or to both Roche/Biogen Idec Inc.’s (RHHBY)/(BIIB – Analyst Report) Rituxan (rituximab) and chemotherapy and who have 
Infinity Reports Updated Phase 1 Data of IPI-145 in Indolent Non-Hodgkin Business Wire (press release)
Infinity Reports Preclinical Data at ASH Annual Meeting in Diffuse Large B MarketWatch

all 25 news articles »